Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors

Next Previous
Trial Profile

Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary)
  • Indications Brain cancer; Clear cell sarcoma; CNS cancer; Diffuse intrinsic pontine glioma; Ependymoma; Glioma; Medulloblastoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms AflacST1501

Most Recent Events

  • 24 Oct 2023 Status changed from recruiting to completed.
  • 18 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
  • 18 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top